Sana Biotechnology Inc vs Western Union Co — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Western Union Co trades at $6.15 (market cap $1.97B). The key difference: Western Union Co is far larger — about 2.4× Sana Biotechnology Inc's market cap, and Western Union Co pays a 14.85% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Western Union Co for 96 Days on average.
| SANA | WU | |
|---|---|---|
Market Cap | $836.71M | $1.97B |
Volume | 4,507,444 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $5.92 | $10.28 |
52-Week Low | $2.68 | $5.90 |
Typical Hold Time | 23 Days | 96 Days |
Enterprise Value | $749.96M | $1.88B |
Dividend Yield | — | 14.85% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Western Union (WU) trades at $6.12, showing minimal daily movement with a 0.16% gain. The stock demonstrates strong profitability with a 43.97% ROE and attractive valuation metrics including a 5.1 P/E ratio. Recent earnings have been mixed with two misses in the last three quarters, while technical indicators show a bullish overall signal despite bearish moving averages. The company's $200 million efficiency plan and Intermex acquisition represent significant strategic initiatives.
WU presents a value opportunity with deep discount valuation, but faces earnings volatility and competitive pressures. The 12.24% analyst buy rating reflects cautious optimism, with the $6.86 consensus target offering 12% upside. Key risks include integration challenges from acquisitions and margin pressure from digital transformation costs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →